Osteocyte deficiency in hip fractures

Jesus Delgado-Calle, Jana Arozamena, Raúl García-Renedo, Carmen García-Ibarbia, María A. Pascual-Carra, Jesús González-Macías, José A. Riancho

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Osteocytes play a central role in the regulation of bone remodeling. The aim of this study was to explore osteocyte function, and particularly the expression of SOST, a Wnt inhibitor, in patients with hip fractures. Serum sclerostin levels were measured by ELISA. The expression of several osteocytic genes was studied by quantitative PCR in trabecular samples of the femoral head of patients with hip fractures, hip osteoarthritis and control subjects. The presence of sclerostin protein and activated caspase 3 was revealed by immunostaining. There were no significant differences in serum sclerostin between the three groups. Patients with fractures have fewer lacunae occupied by osteocytes (60 ± 5% vs. 64 ± 6% in control subjects, P = 0.014) and higher numbers of osteocytes expressing activated caspase 3, a marker of apoptosis. The proportion of sclerostin-positive lacunae was lower in patients with fractures than in control subjects (34 ± 11% vs. 69 ± 10%, P = 2 × 10 -8). The proportion of sclerostinpositive osteocytes was also lower in patients. RNA transcripts of SOST, FGF23 and PHEX were also less abundant in fractures than in control bones (P = 0.002, 5 × 10 -6, and 0.04, respectively). On the contrary, in patients with osteoarthritis, there was a decreased expression of SOST and FGF23, without differences in PHEX transcripts or osteocyte numbers. Osteocyte activity is altered in patients with hip fractures, with increased osteocyte apoptosis and reduced osteocyte numbers, as well as decreased transcription of osteocytic genes. Therefore, these results suggest that an osteocyte deficiency may play a role in the propensity to hip fractures.

Original languageEnglish (US)
Pages (from-to)327-334
Number of pages8
JournalCalcified Tissue International
Volume89
Issue number4
DOIs
StatePublished - Oct 2011
Externally publishedYes

Fingerprint

Osteocytes
Hip Fractures
Caspase 3
Apoptosis
Hip Osteoarthritis
Bone Remodeling
Thigh
Serum
Osteoarthritis
Genes
Enzyme-Linked Immunosorbent Assay
RNA
Bone and Bones

Keywords

  • FGF23
  • Osteocytes
  • Osteoporosis
  • PHEX
  • Sclerostin

ASJC Scopus subject areas

  • Orthopedics and Sports Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Delgado-Calle, J., Arozamena, J., García-Renedo, R., García-Ibarbia, C., Pascual-Carra, M. A., González-Macías, J., & Riancho, J. A. (2011). Osteocyte deficiency in hip fractures. Calcified Tissue International, 89(4), 327-334. https://doi.org/10.1007/s00223-011-9522-0

Osteocyte deficiency in hip fractures. / Delgado-Calle, Jesus; Arozamena, Jana; García-Renedo, Raúl; García-Ibarbia, Carmen; Pascual-Carra, María A.; González-Macías, Jesús; Riancho, José A.

In: Calcified Tissue International, Vol. 89, No. 4, 10.2011, p. 327-334.

Research output: Contribution to journalArticle

Delgado-Calle, J, Arozamena, J, García-Renedo, R, García-Ibarbia, C, Pascual-Carra, MA, González-Macías, J & Riancho, JA 2011, 'Osteocyte deficiency in hip fractures', Calcified Tissue International, vol. 89, no. 4, pp. 327-334. https://doi.org/10.1007/s00223-011-9522-0
Delgado-Calle J, Arozamena J, García-Renedo R, García-Ibarbia C, Pascual-Carra MA, González-Macías J et al. Osteocyte deficiency in hip fractures. Calcified Tissue International. 2011 Oct;89(4):327-334. https://doi.org/10.1007/s00223-011-9522-0
Delgado-Calle, Jesus ; Arozamena, Jana ; García-Renedo, Raúl ; García-Ibarbia, Carmen ; Pascual-Carra, María A. ; González-Macías, Jesús ; Riancho, José A. / Osteocyte deficiency in hip fractures. In: Calcified Tissue International. 2011 ; Vol. 89, No. 4. pp. 327-334.
@article{f9d177d57d5a49b3985ee3457955eacd,
title = "Osteocyte deficiency in hip fractures",
abstract = "Osteocytes play a central role in the regulation of bone remodeling. The aim of this study was to explore osteocyte function, and particularly the expression of SOST, a Wnt inhibitor, in patients with hip fractures. Serum sclerostin levels were measured by ELISA. The expression of several osteocytic genes was studied by quantitative PCR in trabecular samples of the femoral head of patients with hip fractures, hip osteoarthritis and control subjects. The presence of sclerostin protein and activated caspase 3 was revealed by immunostaining. There were no significant differences in serum sclerostin between the three groups. Patients with fractures have fewer lacunae occupied by osteocytes (60 ± 5{\%} vs. 64 ± 6{\%} in control subjects, P = 0.014) and higher numbers of osteocytes expressing activated caspase 3, a marker of apoptosis. The proportion of sclerostin-positive lacunae was lower in patients with fractures than in control subjects (34 ± 11{\%} vs. 69 ± 10{\%}, P = 2 × 10 -8). The proportion of sclerostinpositive osteocytes was also lower in patients. RNA transcripts of SOST, FGF23 and PHEX were also less abundant in fractures than in control bones (P = 0.002, 5 × 10 -6, and 0.04, respectively). On the contrary, in patients with osteoarthritis, there was a decreased expression of SOST and FGF23, without differences in PHEX transcripts or osteocyte numbers. Osteocyte activity is altered in patients with hip fractures, with increased osteocyte apoptosis and reduced osteocyte numbers, as well as decreased transcription of osteocytic genes. Therefore, these results suggest that an osteocyte deficiency may play a role in the propensity to hip fractures.",
keywords = "FGF23, Osteocytes, Osteoporosis, PHEX, Sclerostin",
author = "Jesus Delgado-Calle and Jana Arozamena and Ra{\'u}l Garc{\'i}a-Renedo and Carmen Garc{\'i}a-Ibarbia and Pascual-Carra, {Mar{\'i}a A.} and Jes{\'u}s Gonz{\'a}lez-Mac{\'i}as and Riancho, {Jos{\'e} A.}",
year = "2011",
month = "10",
doi = "10.1007/s00223-011-9522-0",
language = "English (US)",
volume = "89",
pages = "327--334",
journal = "Calcified Tissue International",
issn = "0171-967X",
publisher = "Springer Verlag",
number = "4",

}

TY - JOUR

T1 - Osteocyte deficiency in hip fractures

AU - Delgado-Calle, Jesus

AU - Arozamena, Jana

AU - García-Renedo, Raúl

AU - García-Ibarbia, Carmen

AU - Pascual-Carra, María A.

AU - González-Macías, Jesús

AU - Riancho, José A.

PY - 2011/10

Y1 - 2011/10

N2 - Osteocytes play a central role in the regulation of bone remodeling. The aim of this study was to explore osteocyte function, and particularly the expression of SOST, a Wnt inhibitor, in patients with hip fractures. Serum sclerostin levels were measured by ELISA. The expression of several osteocytic genes was studied by quantitative PCR in trabecular samples of the femoral head of patients with hip fractures, hip osteoarthritis and control subjects. The presence of sclerostin protein and activated caspase 3 was revealed by immunostaining. There were no significant differences in serum sclerostin between the three groups. Patients with fractures have fewer lacunae occupied by osteocytes (60 ± 5% vs. 64 ± 6% in control subjects, P = 0.014) and higher numbers of osteocytes expressing activated caspase 3, a marker of apoptosis. The proportion of sclerostin-positive lacunae was lower in patients with fractures than in control subjects (34 ± 11% vs. 69 ± 10%, P = 2 × 10 -8). The proportion of sclerostinpositive osteocytes was also lower in patients. RNA transcripts of SOST, FGF23 and PHEX were also less abundant in fractures than in control bones (P = 0.002, 5 × 10 -6, and 0.04, respectively). On the contrary, in patients with osteoarthritis, there was a decreased expression of SOST and FGF23, without differences in PHEX transcripts or osteocyte numbers. Osteocyte activity is altered in patients with hip fractures, with increased osteocyte apoptosis and reduced osteocyte numbers, as well as decreased transcription of osteocytic genes. Therefore, these results suggest that an osteocyte deficiency may play a role in the propensity to hip fractures.

AB - Osteocytes play a central role in the regulation of bone remodeling. The aim of this study was to explore osteocyte function, and particularly the expression of SOST, a Wnt inhibitor, in patients with hip fractures. Serum sclerostin levels were measured by ELISA. The expression of several osteocytic genes was studied by quantitative PCR in trabecular samples of the femoral head of patients with hip fractures, hip osteoarthritis and control subjects. The presence of sclerostin protein and activated caspase 3 was revealed by immunostaining. There were no significant differences in serum sclerostin between the three groups. Patients with fractures have fewer lacunae occupied by osteocytes (60 ± 5% vs. 64 ± 6% in control subjects, P = 0.014) and higher numbers of osteocytes expressing activated caspase 3, a marker of apoptosis. The proportion of sclerostin-positive lacunae was lower in patients with fractures than in control subjects (34 ± 11% vs. 69 ± 10%, P = 2 × 10 -8). The proportion of sclerostinpositive osteocytes was also lower in patients. RNA transcripts of SOST, FGF23 and PHEX were also less abundant in fractures than in control bones (P = 0.002, 5 × 10 -6, and 0.04, respectively). On the contrary, in patients with osteoarthritis, there was a decreased expression of SOST and FGF23, without differences in PHEX transcripts or osteocyte numbers. Osteocyte activity is altered in patients with hip fractures, with increased osteocyte apoptosis and reduced osteocyte numbers, as well as decreased transcription of osteocytic genes. Therefore, these results suggest that an osteocyte deficiency may play a role in the propensity to hip fractures.

KW - FGF23

KW - Osteocytes

KW - Osteoporosis

KW - PHEX

KW - Sclerostin

UR - http://www.scopus.com/inward/record.url?scp=82755160854&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=82755160854&partnerID=8YFLogxK

U2 - 10.1007/s00223-011-9522-0

DO - 10.1007/s00223-011-9522-0

M3 - Article

C2 - 21874545

AN - SCOPUS:82755160854

VL - 89

SP - 327

EP - 334

JO - Calcified Tissue International

JF - Calcified Tissue International

SN - 0171-967X

IS - 4

ER -